Lexicon Pharmaceuticals

#6435

Rank

$716.02M

Marketcap

United States

Country

Leadership team

Mr. Lonnel Coats (CEO & Director)

Mr. Jeffrey L. Wade J.D. (Pres & CFO)

Mr. Brian T. Crum (Sr. VP, Gen. Counsel & Sec.)

Products/ Services

Bioinformatics, Biotechnology, Medical, Pharmaceutical

Number of Employees

50 - 100

Headquarters

The Woodlands, Texas, United States

Established

1995

Company Registration

SEC CIK number: 0001062822

Traded as

LXRX

Social Media

URL

https://www.lexpharma.com

Overview

Location

Recognition and Award

References

Summary

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

History

Lexicon Pharmaceuticals was founded in 1995, focusing on the discovery and development of small molecule drugs that modulate gene networks to treat diseases. With groundbreaking technology and a comprehensive set of tools and expertise, Lexicon has been successful in discovery of several novel therapeutic candidates.

Mission

Lexicon’s mission is to discover breakthrough therapies designed to save and improve patients’ lives.

Vision

Lexicon strives to be a global leader in the development and commercialization of medicines that have the potential to translate gene networks into cures for human disease.

Key Team

Mike Kelly (Investor Relations Officer)

Dr. Alan J. Main Ph.D. (Exec. VP of Innovation & Chemical Sciences)

Chas Schultz (Exec. Director of Corp. Communications & Patient Advocacy)

Dr. Craig B. Granowitz M.D., Ph.D. (Sr. VP & Chief Medical Officer)

Ms. Wendy E. McDermott (VP of HR)

Dr. Robert J. Lefkowitz M.D. (Consultant & Independent Director)

Ms. Kristen L. Alexander (VP of Fin. & Accounting)

Recognition and Awards

Lexicon Pharmaceuticals has received multiple awards for its innovative approach to drug discovery, including the Prix Galien USA Award for Best Pharmaceutical Product in 2016 and the Prix Galien USA Award for Best Biotechnology Product in 2017.